

1 **Title:** Severe acute respiratory syndrome (SARS) mathematical models and disease  
2 parameters: a systematic review and meta-analysis

3

4 **Authors:** Christian Morgenstern<sup>1,\*,#</sup>, Thomas Rawson<sup>1,\*</sup>, Isobel Routledge<sup>1</sup>, Mara Kont<sup>1</sup>,  
5 Natsuko Imai-Eaton<sup>1</sup>, Janetta Skarp<sup>1</sup>, Patrick Doohan<sup>1</sup>, Kelly McCain<sup>1</sup>, Rob Johnson<sup>1</sup>, H.  
6 Juliette T. Unwin<sup>4,1</sup>, Tristan Naidoo<sup>1</sup>, Dominic P Dee<sup>1</sup>, Kanchan Parchani<sup>1</sup>, Bethan N  
7 Cracknell Daniels<sup>1</sup>, Anna Vicco<sup>1</sup>, Kieran O. Drake<sup>1</sup>, Paula Christen<sup>1</sup>, Richard J  
8 Sheppard<sup>1</sup>, Sequoia I Leuba<sup>1</sup>, Joseph T Hicks<sup>1</sup>, Ruth McCabe<sup>1</sup>, Rebecca K Nash<sup>1</sup>, Cosmo  
9 N Santoni<sup>1</sup>, *Pathogen Epidemiology Review Group*<sup>m</sup>, Gina Cuomo-Dannenburg<sup>1</sup>, Sabine  
10 van Elsland<sup>1</sup>, Sangeeta Bhatia<sup>1,3,^</sup>, and Anne Cori<sup>1,2^</sup>

11

12 **Affiliations:**

13 <sup>1</sup>MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for  
14 Infectious Disease Modelling, Jameel Institute, School of Public Health, Imperial  
15 College London, UK

16 <sup>2</sup>Health Protection Research Unit in Modelling and Health Economics

17 <sup>3</sup>Modelling and Economics Unit, UK Health Security Agency, London, UK

18 <sup>4</sup>School of Mathematics, University of Bristol, Bristol, UK

19

20 <sup>\*, ^</sup> Contributed equally

21 <sup>m</sup> Membership of group authorship is listed in the Supplementary Information

22 <sup>#</sup> Corresponding author: [c.morgenstern@imperial.ac.uk](mailto:c.morgenstern@imperial.ac.uk)

23

24

25 **Abstract**

26 We conducted a systematic review (PROSPERO CRD42023393345) of severe acute  
27 respiratory syndrome (SARS) transmission models and parameters characterising its  
28 transmission, evolution, natural history, severity, risk factors and seroprevalence. Information  
29 was extracted using a custom database and quality assessment tool.

30 We extracted 519 parameters, 243 risk factors, and 112 models from 288 papers. Our  
31 analyses show SARS is characterised by high lethality (case fatality ratio 10.9%),  
32 transmissibility ( $R_0$  range 1.1-4.59), and is prone to superspreading (20% top infectors  
33 causing up to 91% of infections). Infection risk was highest among healthcare workers and  
34 close contacts of infected individuals. Severe disease and death were associated with age and  
35 existing comorbidities. SARS's natural history is poorly characterised, except for the  
36 incubation period and mean onset-to-hospitalisation.

37 Our associated R package, epireview, contains this database, which can continue to be  
38 updated to maintain a living review of SARS epidemiology and models, thus providing a key  
39 resource for informing response to future coronavirus outbreaks.

40 **Keywords:** SARS-CoV-1, systematic review, epidemiological parameters, transmissibility,  
41 mathematical model.

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

## 60 **Introduction**

61 The COVID-19 pandemic re-emphasised the threat posed by coronaviruses to global health.  
62 Three coronaviruses to date, SARS-CoV-1, MERS-CoV, and SARS-CoV-2, have caused  
63 large disruptive epidemics affecting multiple countries (1–3). SARS-CoV-2 is now endemic  
64 in humans, as are four other coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1),  
65 jointly contributing to a large respiratory infection burden globally (4).

66 SARS-CoV-1 (or SARS-CoV) is the first documented coronavirus to have caused an acute  
67 epidemic in humans. Cases of atypical pneumonia were reported in November 2002 (5), with  
68 the World Health Organization (WHO) issuing a global alert in mid-March 2003 for Severe  
69 Acute Respiratory Syndrome (SARS). Later that month, a new airborne coronavirus, SARS-  
70 CoV-1, was identified as its likely cause (5). A large epidemic ensued, with major health and  
71 economic impacts (6), including over 8,400 reported cases (with ~20% among healthcare  
72 workers (HCWs)) across 32 countries up to mid-2003 (7–9). The epidemic was characterised  
73 by superspreading events, in which many infections occurred in a short timeframe in the  
74 same setting (e.g. hospitals or housing estates), and high fatality, with over 900 deaths  
75 reported globally (10,11). Although no pharmaceutical countermeasures were available at the  
76 time, the epidemic was contained within a few months using traditional control measures,  
77 including risk communication, contact tracing, isolation and quarantine (12,13). These proved  
78 effective, likely due to SARS's natural history, namely limited transmission from  
79 asymptomatic and presymptomatic individuals (6).

80 In July 2003, the WHO declared the outbreak contained. A few sporadic cases, some due to  
81 laboratory infections, emerged after 2003-2004. Nonetheless, SARS-CoV-1 still constitutes a  
82 public health threat, currently on the WHO's list of priority pathogens for research and  
83 development (15). Re-emergence of the virus from animals (bats being its main reservoir  
84 (16)) or from laboratories are concerning prospects. Indeed, there is still no effective  
85 treatment (17), and despite promising advances (18,19), there is no approved vaccine.

86 Many studies have investigated the epidemiology and transmission of SARS, leveraging  
87 high-quality data on cases analysed with modern infectious disease epidemiology and  
88 modelling approaches (20). Although multiple SARS systematic reviews have been published  
89 (21–24) (Supplementary Material (SM) appendix E), they mainly focused on narrow aspects  
90 of SARS epidemiology (e.g. serial intervals, incubation periods or intervention effectiveness),  
91 and their static nature means there is no up-to-date resource providing a live picture of the  
92 latest knowledge on SARS epidemiology and modelling. Our study aims to fill this gap: we  
93 systematically reviewed published peer-reviewed SARS models and key epidemiological  
94 parameters. The extracted data are available in a flexible database that can be updated as new  
95 information is produced.

96 Synthesising estimates of key epidemiological parameters is critical to support the response  
97 to future SARS outbreaks. Robust epidemiological parameter estimates are also key inputs to  
98 mathematical models, which will likely be integral to future outbreak responses. Early  
99 analyses of the COVID-19 pandemic relied on assumptions that the natural history of SARS-  
100 CoV-2 was similar to those of SARS-CoV-1 or MERS-CoV (25,26). Our database will

101 provide vital information to support early modelling efforts for future epidemics of SARS  
102 and novel coronaviruses more broadly.

103

## 104 **Methods**

105 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
106 (PRISMA) guidelines. We registered our study protocol with PROSPERO (International  
107 Prospective Register of Systematic Reviews, #CRD42023393345).

### 108 **Search strategy and selection criteria**

109 We searched PubMed and Web of Science for studies published from database inception up  
110 to March 8, 2019. We repeated the search to include publications up to June 24, 2024.  
111 Results were imported into Covidence (2024) (27) and de-duplicated. Titles and abstracts,  
112 and then full texts were independently screened by two reviewers (selected from CM, TR, IR,  
113 MR, NIE, JS, PD, HJTU, TN, DPD, AC, SB), and conflicts were resolved by consensus.  
114 Non-peer-reviewed literature and non-English language studies were excluded. See  
115 Supplementary Material (SM) A.1 for further details on study selection, SM-Table A.1 for  
116 full inclusion and exclusion criteria and SM-section D for the PRISMA checklists.

### 117 **Data extraction**

118 21% of full texts (n total=288) meeting the inclusion criteria were randomly selected and  
119 double-extracted to validate the extraction process. A consensus on discordant results was  
120 established, after which 20 reviewers (CM, TR, PD, KM, RJ, HJTU, TN, DPD, KP, BNCD,  
121 AV, KOD, PC, RJS, SIL, JTH, RM, RKN, AC, SB) independently conducted single  
122 extraction on the remaining full texts. Data on publication details, quality assessment (using a  
123 customised questionnaire, see Data analysis section and SM-A.5), transmission model details,  
124 basic and effective reproduction numbers, any epidemiological delays (e.g. incubation period  
125 or symptom-onset-to-hospitalisation or -outcome delays), case fatality ratios (CFRs), attack  
126 rates, growth rates, overdispersion, seroprevalence, and risk factors, were extracted using a  
127 Microsoft Access database (version 2305). For risk factors, we extracted only whether-or-not  
128 a factor was statistically significant, as reported in the articles, and if an analysis was adjusted  
129 for other covariates. This is because differences in reference groups and stratification made it  
130 unsuitable to compare other measures (e.g. odds ratios) across studies. We excluded  
131 systematic reviews from our study but used them to cross-check that all eligible studies were  
132 included (SM-section E). Full details of the data extraction process (SM-section A.2),  
133 database structure (SM-tables B.6-B.7) and extracted data (SM-tables B.8-B.13) are provided  
134 in SM.

135

136 Given there is a single documented SARS epidemic, we also analysed information on case  
137 and death numbers reported by country from the final report of the Hong Kong SARS Expert  
138 Committee (HKSEC) (10) to assess the global burden of the epidemic from a single source  
139 without redundancy.

140

141

## 142 **Data analysis**

143 The risk of bias was assessed using a bespoke quality assessment (QA) questionnaire, with  
144 QA scores for each article calculated as the proportion of ‘Yes’ responses to applicable  
145 questions. A local polynomial regression was used to analyse temporal trends in QA scores  
146 (SM-Figure B.1). All manuscript figures show extracted parameters from “high QA” studies  
147 only, i.e. those with a QA score >50% (as in previous work (28)). Results from all studies are  
148 shown in SM Section B.5.1. For each parameter, we declare the total number of parameter  
149 extractions and studies and the number of high QA parameter extractions and studies.

150 Analyses were conducted in *R* (version 4.2.2) (29); curated data on outbreaks, models, and  
151 epidemiological parameters were added to the *epireview* R package (30) (SM-section C).

152 See SM section A.3.4 for how uncertainty is defined across all parameters.

153 Meta-analyses of published estimates were conducted using the *meta* R package (31) for the  
154 mean incubation period and the mean symptom-onset-to-hospital-admission delay. Common  
155 and random effects models were used to generate pooled delay estimates with 95%  
156 confidence interval (CI) and  $I^2$  heterogeneity estimates (SM-A.3). We did not perform meta-  
157 analyses for other parameters due to insufficient estimates of central tendency paired with  
158 sample uncertainty.

159 In addition to our review, we used data from the final HKSEC report (10), including the  
160 number of SARS cases, hospitalisations, deaths, recoveries, imported cases by country, and  
161 the onset dates for the first and last probable cases. We used this dataset to identify countries  
162 with local transmission and calculate CFRs for each country. We used mixed-effect logistic  
163 regression to obtain a pooled CFR estimate (Figure 2, SM-A.3.2).

164

## 165 **Results**

166 The search returned 28,356 potentially relevant articles. De-duplication retained 14,929  
167 articles for title/abstract screening. 878 studies were retained for full-text screening, with 288  
168 studies meeting the criteria for final inclusion (SM-Table A.1). As shown in Figure 1, the  
169 main reasons for study exclusion were “no reported parameters or models of interest”  
170 ( $n=220$ ) and “no original estimates” ( $n=138$ ). We report Cohen’s kappa for the screening and  
171 full-text review (SM-Figure B.13).

172 We extracted 519 parameters and 243 risk factors from 186 articles (SM-Tables B.3-4, B.8-  
173 13 and SM-Figure B.2) and 112 models from 108 articles (SM-Table B.5 and SM-Figure  
174 B.3).

175 [FIGURE 1 here]

176 Figure 2 illustrates the global burden of the 2003-2004 SARS epidemic, as estimated from  
177 the HKSEC final report (10). China reported the most cases (5327), followed by Hong Kong  
178 (1755), Taiwan (665), Canada (251), Singapore (238), and Vietnam (63). Local transmission  
179 was not documented elsewhere, though cases were reported in other countries.

180 [FIGURE 2 here]

181 We extracted 34 basic reproduction number ( $R_0$ ) estimates from 25 studies in total and 25  
182 effective reproduction number ( $R_t$ ) estimates from 13 studies (SM-Tables B.4, B.8).  $R_0$   
183 measures transmission without interventions and population immunity, whilst  $R_t$  captures  
184 transmissibility, including as influenced by immunity, control measures, and behavioural  
185 changes (32). Central  $R_0$  estimates from 13 high-QA studies ranged between 1.1 and 88.3  
186 ( $n=16$ ). We omit two outlying estimates from our main analysis of 88.3 (33) and 12.985 (34)  
187 due to their unique study contexts: one pertains to a nosocomial setting, and the other is from  
188 a study investigating the impact of priors on Bayesian inference. The remaining 14  $R_0$  central  
189 estimates from 11 studies ranged from 1.1 to 4.59, with uncertainty intervals spanning 0.25-  
190 5.31 (Figure 3A).  $R_0$  estimates were similar across countries and the outbreak phase they  
191 were estimated from (Figure 3A and SM-B.4, B.8). As expected,  $R_t$  estimates tended to be  
192 lower. Of the 17  $R_t$  estimates from 8 high-QA studies, 11 had a central value below or at the  
193 threshold  $R_t=1$ , indicating a controlled epidemic, with the remaining six central  $R_t$  estimates  
194 ranging from 2.4 to 4.8 (Figure 3B). All  $R_t$  estimates from the start of the outbreak ( $n=5$ ) were  
195 above 1, while four mid-outbreak, two end-outbreak, and two control-measure period  
196 estimates were below 1.

197 [FIGURE 3 here]

198 Five growth-rate estimates were extracted from three studies, 33 attack rates (AR) from 22  
199 studies, and nine secondary attack rates from eight studies (SM-Tables B.4, B.8).

200 Growth rate central estimates ranged from 4.22%, corresponding to the midpoint of the range  
201 of captured estimates in Zhang et al (35), to 16% per day (four estimates from two high-QA  
202 studies, all estimated in the presence of control measures, Figure 4C), corresponding to a  
203 doubling time between 4 and 16 days (SM-A.3).

204 AR estimates from the general population exclusively were generally low, with all but one  
205 central estimate of high-QA studies ranging from 0 to 5.18%, corresponding to the mid-point  
206 of the range of captured estimates of Rea et al (36) ( $n=11$  from six studies) and one higher  
207 estimate at 16.4% (Figure 4A). ARs in HCWs were substantially higher, with central  
208 estimates ranging from 0.47 to 35.15% ( $n=7$  from seven high-QA studies), as were ARs in  
209 persons under investigation (close contacts or targeted studies), with central estimates ranging  
210 from 0 to 40.5% ( $n=5$  from four high-QA studies).

211 Secondary ARs showed a similar trend, with high estimates for HCWs (two central estimates  
212 from two high-QA studies ranging from 18.7 - 19%) and persons under investigation (two  
213 central estimates from two high-QA studies - 10.2 and 42.6%, corresponding to the mid-  
214 point of the range of captured estimates of Shen et al (37)), and lower estimates in other  
215 settings (three central estimates from two high-QA studies ranging from 6.2 to 14.9%, Figure  
216 4B).

217 Overdispersion characterises heterogeneity in the number of secondary cases generated by  
218 one individual, with lower overdispersion estimates indicating more heterogeneity or  
219 superspreading. We extracted eight estimates of overdispersion from four studies (SM-B.8);

220 seven estimates for the three high-QA studies had central estimates ranging from  $7.52 \times 10^{-7}$   
221 to 0.285, with uncertainty extending as high as 1.48 (Figure 4D).

222

223 We extracted 12 parameters detailing genetic mutation from six studies in total. Filtering for  
224 only high QA studies, we extracted two mutation rate (evolutionary rate) estimates from two  
225 studies, one of which also reported three substitution rate estimates (Figure 4E-F, SM-Table  
226 B.8). Central estimates ranged from 14 to  $30.15 \times 10^{-4}$  substitutions per site per year (s/s/y)  
227 for the evolutionary rate and from 15.90 to  $50.15 \times 10^{-4}$  s/s/y for the substitution rate, where  
228 the central estimate corresponds to the mid-point of the range of captured estimates for each  
229 study. Uncertainty around those was not reported, but ranges of point estimates were  
230 provided, e.g. reflecting different fragments of the genome considered: one study reported  
231 central evolutionary rate estimates ranging from 4.2 to  $23.4 \times 10^{-4}$  s/s/y, and three studies  
232 reported wide ranges of central substitution rates estimates, from 0 to  $92.20 \times 10^{-4}$  s/s/y.

233

234 [FIGURE 4 here]

235 Seroprevalence estimates varied widely across studies, again depending on the population  
236 being investigated (SM-Table B.12), with low seroprevalence in the general population and  
237 children and mixed groups outside hospital settings (8 seroprevalence estimates from 0 to  
238 12.04% across five high-QA studies), moderate in HCWs (13 seroprevalence estimates from  
239 0 to 88.9% across 11 high-QA studies), and high in persons under investigation (nine  
240 seroprevalence estimates from 0.19 to 100% across nine high-QA studies).

241

242 37 studies (31 high-QA) examined risk factors for SARS infection (SM-Table B.13, SM-  
243 Figure B.11-12). Most risk factors considered were found to be both non-significant and  
244 significant across different studies. Close or household contact with an infected individual  
245 and occupation were more frequently significantly (vs. non-significantly) associated with  
246 infection (SM-Figure B.11 A). In contrast, age, sex and comorbidity were more likely to be  
247 non-significantly (vs. significantly) associated with infection.

248 We extracted 116 CFR estimates from 77 articles (86 estimates from 56 high-QA studies)  
249 (SM-Table B.4 and B.11, SM-Figure B.2). Half of these (n=57 estimates from 42 studies)  
250 were computed using a naïve approach (i.e. dividing the number of deaths by the number of  
251 cases), which leads to biased estimates if some cases have unknown final status. This can  
252 often be the case in real-time analyses (38). Many studies did not explicitly specify the CFR  
253 estimation method (n=37 estimates from 24 studies). Of those which corrected for right  
254 censoring (n=22 estimates from 14 studies), CFR estimates ranged from 0.1 to 30.8%. Many  
255 studies were for the same countries (e.g., nine CFR estimates from four studies for China);  
256 hence, estimates were likely not independent. We, therefore, also estimated the CFR  
257 retrospectively from data in the HKSEC final report (10); the CFR varied by country, from  
258 6.6% (95% confidence interval (CI) 5.9-7.2%) in mainland China to 27.1% (95% CI 23.7-  
259 30.6%) in Taiwan, with a pooled random effect estimate of 13.8% (95% CI 9.2-20.3%) and a  
260 pooled common effect estimate of 10.9% (95% CI 10.3-11.6%, Figure 2).

261 Many studies considered potential risk factors for severe disease (21 analyses from eight  
262 studies, SM-Figure B.11 B, ten analyses from three high-QA studies) or death (82 analyses  
263 from 36 studies, SM-Figure B.11 C, 62 from 27 high-QA studies). Age, comorbidities and  
264 sex were the most studied risk factors for both severe disease and death (SM Figure B.10).  
265 Most analyses found age and comorbidities to be significant risk factors for severe disease  
266 and death. Most studies that considered sex as a risk factor for severe disease found it to be  
267 significant; there was mixed evidence of sex being a risk factor for death (14 studies  
268 significant versus 12 studies not significant). Contacts with infected individuals, in or outside  
269 the household, were not found to be a significant risk factor for severe disease ( $n = 1$  analysis  
270 from one study), but close contact was identified as a significant risk factor for death in three  
271 out of four analyses from three studies. Occupation and hospitalisation were often identified  
272 as significant risk factors for death (10 analyses from eight studies and three analyses from  
273 two studies, respectively).

274

275 We extracted three estimates of mean serial interval (SI) from two studies and seven  
276 estimates of the infectious period from seven studies (Figure 5A-B and SM-Table C.10). The  
277 three SI estimates (all from high-QA studies) were broadly consistent, albeit uncertainty was  
278 large, encompassing values from 6.77 to 18.55 days. Four central estimates of the infectious  
279 period across four high-QA studies ranged from 4.84 to 10 days (uncertainty range 5.8-14.3  
280 days; note not all studies report uncertainty), with a fifth high-QA study yielding a much  
281 higher central estimate of 21.6 days (uncertainty 14.9 to 26.8 days).

282

283 We extracted 49 incubation period estimates from 39 studies, with 42 estimates from 32 high-  
284 QA studies, including 17 estimates with sufficient information for inclusion in a meta-  
285 analysis (Figure 5D and SM-Table B.10). The pooled mean incubation period estimate was  
286 5.03 days (95% CI 4.87-5.18) using a common effects (CE) model, and 5.42 days (95% CI  
287 4.75-6.09) using a random effects (RE) model. The high  $I^2$  (93%) suggests substantial  
288 heterogeneity across studies. Meta-analyses restricted to specific study populations (general  
289 population, HCWs, mixed groups, and persons under investigation) highlighted small  
290 differences in the mean incubation period across populations, with high  $I^2$  throughout,  
291 indicating high heterogeneities between studies within each subgroup. The mean incubation  
292 period was shortest in persons under investigation (RE estimate 4.93 days, 95% CI 4.01-5.85)  
293 and longest in the general population (6.33, 95% CI 4.86-7.80).

294

295 We extracted 38 estimates of the delay from onset of symptoms to hospitalisation from 33  
296 studies, including 29 estimates from 25 high-QA studies eligible for inclusion in meta-  
297 analysis (Figure 5E and SM-Table B.10). The estimated mean onset-to-hospitalisation delay  
298 was 3.48 days (95% CI 3.34-3.62 days) using the CE model and 3.99 days (95% CI 3.29-4.69  
299 days) using the RE model, with a high  $I^2$  (95%) suggesting large heterogeneity across studies.

300

301 We extracted 21 estimates from 14 studies characterising the delay from hospitalisation to  
302 outcome (i.e. death or recovery, Figure 5C and SM-Table B.10). Central estimates ranged  
303 from 9.4 to 35.9 days for the mean time from hospitalisation to death (seven estimates from



304 six high-QA studies) and from 19 to 29.7 days for the mean time from hospitalisation to  
305 recovery (six estimates from six high-QA studies). We also extracted 15 estimates from 14  
306 studies of mean time in hospital, with central estimates ranging from 3 to 23 days across  
307 seven high-QA studies.

308 We conducted our meta-analyses using only high-QA studies. None of the lower-QA studies  
309 provided sufficient information to be included in our meta-analyses; hence, these did not  
310 affect our results (SM-Figure B.6).

311  
312

[FIGURE 5 here]

313 112 SARS transmission models were extracted from 108 studies (SM-Figure B.3, SM-Tables  
314 B.5, B.9). Compartmental models were the most frequent model type (n=63 from 62 studies),  
315 followed by individual-based models (n=9 from nine studies), and branching processes (n=7  
316 from seven studies). Most compartmental models (n=43 of 63) were deterministic.  
317 Approximately half of the extracted models had been calibrated using observed data. Models  
318 captured a wide range of interventions, including quarantine and contact tracing, as well as  
319 behaviour changes (SM-Figure B.3(F)). No model had publicly available code.  
320

## 321 Discussion

322 In this systematic review, we compiled and analysed published epidemiological parameter  
323 estimates and mathematical models of SARS-CoV-1. SARS epidemiology has been well  
324 characterised overall, with 519 epidemiological parameters, 243 risk factors, and 112  
325 mathematical models extracted in this review, covering multiple geographic regions affected  
326 by the 2003-2004 epidemic (Figure 2, SM-Figure B2). Synthesising this information in a  
327 central dynamic database, as we have done in the R package *epireview*, is critical to prepare  
328 for potential future outbreaks of SARS-CoV-1, a high-threat virus on the 2024 WHO list of  
329 priority pathogens (39). This central resource will also be useful for epidemic preparedness,  
330 to characterise the epidemiology of existing coronaviruses and anticipate the potential  
331 epidemiological profile of future ones.

332 SARS was first detected in China and then affected multiple other countries. Unlike with  
333 SARS-CoV-2, however, international spread was limited, with local transmission only  
334 identified in a handful of countries.

335 However, SARS transmissibility in the affected regions was high, with growth rate estimates  
336 translating into a doubling of cases every 4 to 16 days (Figure 4 growth rates converted to  
337 doubling times (SI A.3)), and  $R_0$  estimates broadly ranging from 1.1-4.59 (Figure 3A). These  
338  $R_0$  estimates were obtained using varied statistical approaches and data types. They were  
339 reported in very heterogeneous formats, sometimes without any characterisation of  
340 uncertainty, making comparison and synthesis across studies challenging. These  $R_0$  estimates  
341 are comparable to those for the SARS-CoV-2 wildtype (~2.5) (40) and generally slightly  
342 higher than for pandemic influenza (typically 1-2.5) (41-43). Detection of the SARS  
343 epidemic and the subsequent WHO global alert rapidly prompted interventions, including  
344 quarantine, isolation, strict hygiene measures in hospitals and social distancing (13,44). These  
345 eventually led to a decline in cases, consistent with a reduction of  $R_t$ : estimates at the start of  
346 the epidemic broadly align with the basic reproduction number, ranging from 2-4 (Figure

347 3B), whilst estimates later in the epidemic suggest interventions were effective, bringing  $R_t$   
348 below 1.

349 However, transmission was highly heterogeneous: overdispersion estimates suggest  
350 significant variations in the number of secondary infections generated by each case.  
351 Following the approach of Lloyd-Smith et al. (45), the range of central overdispersion  
352 estimates (between  $7.52 * 10^{-7}$  (post interventions) and 0.285 (pre interventions), Figure 4)  
353 suggests that approximately 91% of SARS-CoV-1 transmission can be attributed to the 20%  
354 most infectious individuals in the pre-intervention period but this increases to 99% in the  
355 post-intervention period (SI A.3.3). Hence, superspreading in SARS-CoV-1 is more  
356 prominent than for many other viruses (45), including SARS-CoV-2 (46). This characteristic  
357 makes SARS particularly threatening, as higher levels of superspreading make epidemics  
358 harder to control.

359 Attack rate, secondary attack rate, and seroprevalence estimates extracted in this review show  
360 that SARS-CoV-1 transmissibility highly depended on the sub-population considered, as  
361 observed during the COVID-19 pandemic (47). General population studies reported SARS-  
362 CoV-1 attack rates and seroprevalence generally under 1% (Figure 4A and SM-Table B.12),  
363 whilst estimates among HCWs were substantially higher, with central estimates ranging from  
364 1.2% to 35.15%.

365 We extracted risk factors associated with infection (SM-Figure B.11). Unsurprisingly, close  
366 contact with confirmed cases was frequently identified as a significant risk factor for  
367 infection. Occupation, including HCWs, was also often reported as a significant risk factor  
368 for infection, in line with higher attack rates, secondary attack rates, and seroprevalence  
369 estimated among HCWs.

370 Published estimates of CFR suggest high severity, with >10% of cases fatal (SM-Table B.11  
371 and Figure 2). This is one order of magnitude higher than SARS-CoV-2 (CFR up to ~2% for  
372 the most severe variants (48) (40)) and pandemic influenza (CFR up to ~1-3% for the 1918  
373 influenza pandemic (49)). Such high severity likely aided case identification and intervention  
374 targeting. However, combined with a relatively high transmissibility and high  
375 superspreading, it emphasises the threat posed by SARS-CoV-1 and potential future  
376 coronaviruses that could share these characteristics.

377 Risk factors for hospitalisation and death were aligned with those previously identified for  
378 respiratory viruses, including age and comorbidities. Sex demonstrated mixed results, with  
379 studies equally identifying it as a significant and non-significant risk factor for SARS  
380 mortality. For COVID-19, the CFR is higher for men than for women (50). Being an HCW  
381 was frequently identified as being significantly associated with the risk of death. However,  
382 these results should be interpreted with caution as we did not extract the direction of the  
383 association.

384 The natural history of SARS was less well-characterised. We identified only three estimates  
385 for the central estimate of the SI, all with considerable uncertainty (Figure 5A) and one  
386 estimate for the generation time. The few estimates for the infectious period suggested a  
387 duration of around a week. However, some uncertainty and an outlier again suggested a much  
388 longer infectious period of several weeks (Figure 5B). The mean incubation period was better

389 characterised, enabling a meta-analysis yielding a pooled RE model estimate of 5.42 days  
390 (95% CI 4.75-6.09, Figure 5D), similar to estimates for SARS-CoV-2 (51). Subgroup  
391 analyses suggested variations in mean incubation periods across populations, although this  
392 may reflect differences in study designs and associated biases. Although not a focus of our  
393 systematic review, very little evidence was found to suggest a role of asymptomatic  
394 transmission for SARS. This suggests that most SARS-CoV-1 infectious individuals were  
395 symptomatic, and their infectiousness started after symptoms, meaning that the latent period  
396 would be at least as long as the incubation period (52,53). Little or no asymptomatic  
397 transmission enables containment, as infectious individuals can be effectively isolated  
398 following symptom onset. This contrasts with SARS-CoV-2, where asymptomatic  
399 transmission has been widely documented, limiting the effectiveness of control measures that  
400 rely on symptom-based case identification and isolation (54).

401 Delay from symptom onset to hospitalisation is also an important marker of epidemic  
402 management, with shorter delays characterising epidemics where cases are isolated more  
403 promptly and which are more likely to be controlled. Our meta-analysis estimated a relatively  
404 short mean time from symptoms to hospitalisation of 3.99 days (95% CI 3.29-4.69) for the  
405 RE model. However, there were substantial variations between studies, with no clear  
406 indications of what factors may drive such heterogeneity (Figure 5E, SM-Figure B.8), except  
407 that the delay reduced over time due to improved population awareness (55). Further studies  
408 into drivers of delayed hospitalisation may help to control outbreaks of SARS-CoV-1 and  
409 other coronaviruses. Estimates of mean time in hospital were also highly variable between  
410 studies, even when considering only individuals who die or only individuals who recover  
411 (Figure 5C). Similarly, further investigation of drivers of such heterogeneity would help  
412 adequately prepare increased healthcare capacity for future coronavirus outbreaks.

413 We identified only two high-QA studies reporting estimates of the substitution and  
414 evolutionary rates for SARS-CoV-1, with widely ranging estimates for different genome  
415 sections. The paucity of estimates is unsurprising given that the SARS epidemic happened  
416 early in the 21<sup>st</sup> century when genetic sequencing was not yet commonly utilised. The higher  
417 end of those ranges, with evolutionary rates up to  $8 \times 10^{-3}$  substitutions per site per year,  
418 emphasises the potential for SARS and similar coronaviruses to evolve rapidly, possibly even  
419 faster than SARS-CoV-2 (56).

420 SARS modelling studies have been continuously published since 2003. Most modelling  
421 studies contemporary with the 2003-2004 epidemic sought to infer epidemiological  
422 parameters and forecast epidemic trends based on data. In contrast, more recent modelling  
423 studies have predominantly been theoretical, using SARS as a case study to explore  
424 methodological questions. While the QA scores of non-modelling studies remained broadly  
425 constant, we noted a decline in QA scores of modelling studies over time (SM-Figure B1  
426 (C)), possibly reflecting this shifting focus.

427 None of the modelling studies provided associated model code, in line with recent estimates  
428 that only 0.5% of medical studies to date provide public-access code (57). The absence of  
429 code also likely reflects a less widespread practice of open-source code in 2003 compared to  
430 2024, with journals and funders requiring open-source code only recently (58).

431 Our work has limitations. Firstly, we excluded non-peer-reviewed literature and studies not in  
432 English from our review. Restriction to peer-reviewed papers ensures our review adheres to  
433 high-quality standards. The language restriction means that we may have excluded relevant  
434 studies, particularly those in Chinese (SM-Table F.17). Secondly, to keep this review  
435 manageable given the volume of peer-reviewed studies on SARS-CoV-2, we added a  
436 “SARS-CoV-2” exclusion term to our search criteria. Therefore, studies comparing SARS-  
437 CoV-1 and SARS-CoV-2 will have been omitted. Overall, given that the literature on SARS  
438 is based on a single well-documented epidemic, it is unlikely that these restrictions left out  
439 substantial pieces of knowledge not otherwise covered. Moreover, further relevant literature  
440 not covered here could, in the future, be added to our ‘epireview’ R package, where all  
441 information extracted in this review is already publicly available (30).

442 When SARS-CoV-2 was first identified, initial assessments of potential epidemic impact and  
443 intervention options were informed by epidemiological and modelling analyses which, in the  
444 absence of characterisation of the new coronavirus, assumed that its natural history and  
445 epidemiology (e.g. degree of superspreading) would be similar to those of SARS-CoV-1 and  
446 MERS-CoV (25,26,59–61). Similar assumptions may need to be made in future outbreaks.  
447 Our systematic review and dynamic database will provide a critical resource to support the  
448 timely development and robust parameterisation of mathematical models in future epidemics  
449 of SARS and novel coronaviruses.

450

## 451 **Declarations**

452 **Funding** All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global  
453 Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global  
454 Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research  
455 Protection Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency  
456 (UKHSA), Imperial College London, and London School of Hygiene & Tropical Medicine (grant code  
457 NIHR200908). AC was supported by the Academy of Medical Sciences Springboard scheme, funded by the  
458 Academy of Medical Sciences, the Wellcome Trust, the UK Department for Business, Energy, and Industrial  
459 Strategy, the British Heart Foundation, and Diabetes UK (reference SBF005\1044) and acknowledges research  
460 funding from the Sergei Brin foundation. CM acknowledges the Schmidt Foundation for research funding (grant  
461 code 6–22–63345). PD, TN, KP acknowledge funding from Community Jameel. RJ acknowledges funding from  
462 CEPI. GC-D acknowledges funding from the Royal Society. KD acknowledges research funding from the  
463 Wellcome Trust (220885/Z/20/Z). RKN acknowledges research funding from the MRC Doctoral Training  
464 Partnership (grant MR/N014103/1). KM acknowledges research funding from the Imperial College President’s  
465 PhD Scholarship. The funders of the study had no role in study design, data collection, data analysis, data  
466 interpretation, or writing of the report. For the purpose of open access, the author has applied a ‘Creative  
467 Commons Attribution’ (CC BY) licence to any Author Accepted Manuscript version arising from this  
468 submission.

## 469 **Availability of data and materials**

470 <https://github.com/mrc-ide/epireview/tree/main/data>

471 **Code availability** <https://github.com/mrc-ide/epireview> ; <https://github.com/mrc-ide/priority-pathogens>

472 **PROSPERO** CRD42023393345

473 ([https://www.crd.york.ac.uk/prospéro/display\\_record.php?RecordID&RecordID=393345](https://www.crd.york.ac.uk/prospéro/display_record.php?RecordID&RecordID=393345))

474 **Competing interests** AC reports payment from Pfizer for teaching mathematical modelling of infectious

475 diseases. PD reports payment from WHO for consulting on integrated modelling. RM has received payment  
476 from WHO for work on MERS-CoV. HJTU reports payment from the Moderna Charitable Foundation (paid  
477 directly to institution for an unrelated project). All other authors declare no competing interests. The views  
478 expressed are those of the authors and not necessarily those of the National Institute for Health and Care  
479 Research (NIHR), UK Health Security Agency, or the Department of Health and Social Care. NI-E is currently  
480 employed by Wellcome. However, Wellcome had no role in the design and conduct of the study; collection,  
481 management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and  
482 decision to submit the manuscript for publication.

#### 483 **Authors' contributions**

484 SB, SvE, AC, and NI-E conceptualised this systematic review. CM, TR, IR, MR, NIE, JS, HJTU, AC, and SB  
485 searched the literature and screened the titles and abstracts. CM, TR, IR, MR, JS, PD, HJTU, TN, DPD, and AC  
486 reviewed all full-text articles. CM, TR, PD, KM, RJ, HJTU, TN, DPD, KP, BNCD, AV, KOD, PC, RJS, SIL,  
487 JTH, RM, RKN, AC, and SB extracted the data. CM, TR, AC and SB formally analysed, visualised, and  
488 validated the data. CM, TR, TN, CNS, and SB were responsible for software infrastructure. AC acquired  
489 funding. CM, TR, and AC were responsible for project administration. GC-D, HJTU, and RKN were  
490 responsible for training individuals on accessing Covidence and designing the Access system. CM and AC  
491 supervised the systematic review. CM, TR, AC, and SB wrote the original manuscript draft. All authors were  
492 responsible for the methodology and review and editing of the manuscript. All authors debated, discussed,  
493 edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to  
494 submit the manuscript for publication.

495

#### 496 **References**

- 497 1. Chowell G, Fenimore PW, Castillo-Garsow MA, Castillo-Chavez C. SARS outbreaks  
498 in Ontario, Hong Kong and Singapore: the role of diagnosis and isolation as a control  
499 mechanism. *J Theor Biol.* 2003 Sep;224(1):1–8.
- 500 2. Cotten M, Watson SJ, Kellam P, Al-Rabeeh AA, Makhdoom HQ, Assiri A, et al.  
501 Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi  
502 Arabia: a descriptive genomic study. *The Lancet.* 2013 Dec;382(9909):1993–2002.
- 503 3. CMMID COVID-19 Working Group, Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M.  
504 The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130  
505 countries and territories. *BMC Med.* 2021 Dec;19(1):40.
- 506 4. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic  
507 Human Coronaviruses. In: *Advances in Virus Research* [Internet]. Elsevier; 2018 [cited 2024  
508 Jun 17]. p. 163–88. Available from:  
509 <https://linkinghub.elsevier.com/retrieve/pii/S0065352718300010>
- 510 5. CDC. CDC SARS Response Timeline [Internet]. 2013. Available from:  
511 [https://archive.cdc.gov/www\\_cdc\\_gov/about/history/sars/timeline.htm#:~:text=SARS%3A%  
512 20Key%20Events,was%20stopped%20in%20July%202003.](https://archive.cdc.gov/www_cdc_gov/about/history/sars/timeline.htm#:~:text=SARS%3A%20Key%20Events,was%20stopped%20in%20July%202003.)
- 513 6. Lee JW, McKibbin WJ. Learning from SARS: Preparing for the Next Disease  
514 Outbreak: Workshop Summary. [Internet]. National Academies Press; 2004. Available from:

- 515 <https://www.ncbi.nlm.nih.gov/books/NBK92473/>
- 516 7. Xiao J, Fang M, Chen Q, He B. SARS, MERS and COVID-19 among healthcare  
517 workers: A narrative review. *J Infect Public Health*. 2020 Jun;13(6):843–8.
- 518 8. WHO. Severe Acute Respiratory Syndrome (SARS) [Internet]. Available from:  
519 [https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab\\_1](https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab_1)
- 520 9. WHO. SARS outbreak contained worldwide [Internet]. WHO; 2003 Jul. Available  
521 from: <https://www.who.int/news/item/05-07-2003-sars-outbreak-contained-worldwide>
- 522 10. Hong Kong SARS Expert Committee. SARS in Hong Kong: from Experience to  
523 Action, Chapter 4 - Commentary on Key Issues [Internet]. 2003. Available from:  
524 [https://www.sars-expertcom.gov.hk/english/reports/reports/files/e\\_chp4.pdf](https://www.sars-expertcom.gov.hk/english/reports/reports/files/e_chp4.pdf)
- 525 11. Severe Acute Respiratory Syndrome (SARS) Epidemiology Working Group.  
526 Consensus document on the epidemiology of severe acute respiratory syndrome (SARS)  
527 [Internet]. WHO; 2003. Report No.: WHO/CDS/CSR/GAR/2003.11. Available from:  
528 [https://iris.who.int/bitstream/handle/10665/70863/WHO\\_CDS\\_CSR\\_GAR\\_2003.11\\_eng.pdf](https://iris.who.int/bitstream/handle/10665/70863/WHO_CDS_CSR_GAR_2003.11_eng.pdf?sequence=1&isAllowed=y)  
529 ?sequence=1&isAllowed=y
- 530 12. Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, Hedley AJ, et al.  
531 Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public  
532 Health Interventions. *Science*. 2003 Jun 20;300(5627):1961–6.
- 533 13. Bell DM, World Health Organization Working Group on Prevention of International  
534 and Community Transmission of SARS. Public Health Interventions and SARS Spread,  
535 2003. *Emerg Infect Dis*. 2004 Nov;10(11):1900–6.
- 536 14. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious  
537 disease outbreak controllable. *Proc Natl Acad Sci*. 2004 Apr 20;101(16):6146–51.
- 538 15. WHO. Prioritizing diseases for research and development in emergency contexts  
539 [Internet]. Available from: [https://www.who.int/activities/prioritizing-diseases-for-research-](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)  
540 [and-development-in-emergency-contexts](https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts)
- 541 16. Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton B. Review of Bats and SARS.  
542 *Emerg Infect Dis*. 2006;12(12):1834–40.
- 543 17. Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects.  
544 Low D, editor. *PLoS Med*. 2006 Sep 12;3(9):e343.
- 545 18. Cankat S, Demael MU, Swadling L. In search of a pan-coronavirus vaccine: next-  
546 generation vaccine design and immune mechanisms. *Cell Mol Immunol*. 2023 Dec  
547 26;21(2):103–18.
- 548 19. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. A

- 549 SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy  
550 adults in a Phase I clinical trial. *Vaccine*. 2008 Nov;26(50):6338–43.
- 551 20. Olowokure B, Merianos A, Leitmeyer K, Mackenzie JS. Focus: SARS. *Nat Rev*  
552 *Microbiol*. 2004 Feb;2(2):92–92.
- 553 21. Vink MA, Bootsma MCJ, Wallinga J. Serial Intervals of Respiratory Infectious  
554 Diseases: A Systematic Review and Analysis. *Am J Epidemiol*. 2014 Nov 1;180(9):865–75.
- 555 22. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation  
556 periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis*. 2009  
557 May;9(5):291–300.
- 558 23. Teasdale E, Santer M, Geraghty AWA, Little P, Yardley L. Public perceptions of non-  
559 pharmaceutical interventions for reducing transmission of respiratory infection: systematic  
560 review and synthesis of qualitative studies. *BMC Public Health*. 2014 Dec;14(1):589.
- 561 24. Kwok KO, Tang A, Wei VWI, Park WH, Yeoh EK, Riley S. Epidemic Models of  
562 Contact Tracing: Systematic Review of Transmission Studies of Severe Acute Respiratory  
563 Syndrome and Middle East Respiratory Syndrome. *Comput Struct Biotechnol J*.  
564 2019;17:186–94.
- 565 25. Imai N, Dorigatti I, Cori A, Riley S, Ferguson N. Estimating the potential total  
566 number of novel Coronavirus cases in Wuhan City, China [Internet]. Imperial College  
567 London; 2020 Jan [cited 2024 Jul 23]. Available from:  
568 <http://spiral.imperial.ac.uk/handle/10044/1/77149>
- 569 26. Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly C, Riley S, et al. Report 3:  
570 Transmissibility of 2019-nCoV [Internet]. Imperial College London; 2020 Jan [cited 2024 Jul  
571 23]. Available from: <http://spiral.imperial.ac.uk/handle/10044/1/77148>
- 572 27. Veritas Health Innovation. Covidence systematic review software [Internet].  
573 Melbourne, Australia: Veritas Health Innovation; 2024. Available from: [www.covidence.org](http://www.covidence.org)
- 574 28. Nash RK, Bhatia S, Morgenstern C, Doohan P, Jorgensen D, McCain K, et al. Ebola  
575 virus disease mathematical models and epidemiological parameters: a systematic review.  
576 *Lancet Infect Dis*. 2024 Aug;S1473309924003748.
- 577 29. R Core Team. R: A Language and Environment for Statistical Computing [Internet].  
578 Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from:  
579 <https://www.R-project.org/>
- 580 30. Nash R, Morgenstern C, Santoni C, Bhatia S, Sheppard R, Hicks J, et al. epireview:  
581 Tools to update and summarise the latest pathogen data from the Pathogen Epidemiology  
582 Review Group (PERG) [Internet]. 2024. Available from: <https://mrc-ide.github.io/epireview/>

- 583 31. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a  
584 practical tutorial. *Evid Based Ment Health*. 2019;(22):153–60.
- 585 32. Fraser C. Estimating Individual and Household Reproduction Numbers in an  
586 Emerging Epidemic. Galvani A, editor. *PLoS ONE*. 2007 Aug 22;2(8):e758.
- 587 33. Kwok KO, Leung GM, Lam WY, Riley S. Using models to identify routes of  
588 nosocomial infection: a large hospital outbreak of SARS in Hong Kong. *Proc R Soc B Biol*  
589 *Sci*. 2007 Mar 7;274(1610):611–8.
- 590 34. Moser CB, Gupta M, Archer BN, White LF. The Impact of Prior Information on  
591 Estimates of Disease Transmissibility Using Bayesian Tools. Van Boven M, editor. *PLOS*  
592 *ONE*. 2015 Mar 20;10(3):e0118762.
- 593 35. Zhang Z. The outbreak pattern of SARS cases in China as revealed by a mathematical  
594 model. *Ecol Model*. 2007 Jun;204(3–4):420–6.
- 595 36. Rea E, Laflèche J, Stalker S, Guarda BK, Shapiro H, Johnson I, et al. Duration and  
596 distance of exposure are important predictors of transmission among community contacts of  
597 Ontario SARS cases. *Epidemiol Infect*. 2007 Aug;135(6):914–21.
- 598 37. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, et al. Superspreading SARS Events,  
599 Beijing, 2003. *Emerg Infect Dis*. 2004 Feb;10(2):256–60.
- 600 38. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, et al. Methods for  
601 Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease. *Am J*  
602 *Epidemiol*. 2005 Sep 1;162(5):479–86.
- 603 39. WHO. Pathogens prioritization: a scientific framework for epidemic and pandemic  
604 research preparedness [Internet]. 2024. Available from:  
605 [https://www.who.int/publications/m/item/pathogens-prioritization-a-scientific-framework-](https://www.who.int/publications/m/item/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness)  
606 [for-epidemic-and-pandemic-research-preparedness](https://www.who.int/publications/m/item/pathogens-prioritization-a-scientific-framework-for-epidemic-and-pandemic-research-preparedness)
- 607 40. Perez-Guzman PN, Knock E, Imai N, Rawson T, Elmaci Y, Alcada J, et al.  
608 Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. *Nat*  
609 *Commun*. 2023 Jul 17;14(1):4279.
- 610 41. Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, Ramasco JJ, et al. Seasonal  
611 transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo  
612 likelihood analysis based on human mobility. *BMC Med*. 2009 Dec;7(1):45.
- 613 42. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza.  
614 *Nature*. 2004 Dec;432(7019):904–6.
- 615 43. Boëlle P, Ansart S, Cori A, Valleron A. Transmission parameters of the A/H1N1  
616 (2009) influenza virus pandemic: a review. *Influenza Other Respir Viruses*. 2011



- 617 Sep;5(5):306–16.
- 618 44. WHO. Disease Outbreak News, 2003 - China [Internet]. 2003 Jul. Available from:  
619 [https://www.who.int/emergencies/disease-outbreak-news/item/2003\\_07\\_04-en](https://www.who.int/emergencies/disease-outbreak-news/item/2003_07_04-en)
- 620 45. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of  
621 individual variation on disease emergence. *Nature*. 2005 Nov;438(7066):355–9.
- 622 46. Wegehaupt O, Endo A, Vassall A. Superspreading, overdispersion and their  
623 implications in the SARS-CoV-2 (COVID-19) pandemic: a systematic review and meta-  
624 analysis of the literature. *BMC Public Health*. 2023 May 30;23(1):1003.
- 625 47. Ferland L, Carvalho C, Gomes Dias J, Lamb F, Adlhoch C, Suetens C, et al. Risk of  
626 hospitalization and death for healthcare workers with COVID-19 in nine European countries,  
627 January 2020–January 2021. *J Hosp Infect*. 2022 Jan;119:170–4.
- 628 48. Luo G, Zhang X, Zheng H, He D. Infection fatality ratio and case fatality ratio of  
629 COVID-19. *Int J Infect Dis*. 2021 Dec;113:43–6.
- 630 49. Napoli C, Fabiani M, Rizzo C, Barral M, Oxford J, Cohen JM, et al. Assessment of  
631 human influenza pandemic scenarios in Europe. *Eurosurveillance* [Internet]. 2015 Feb 19  
632 [cited 2024 Jul 20];20(7). Available from:  
633 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2015.20.7.21038>
- 634 50. Green MS, Nitzan D, Schwartz N, Niv Y, Peer V. Sex differences in the case-fatality  
635 rates for COVID-19—A comparison of the age-related differences and consistency over  
636 seven countries. Flacco ME, editor. *PLOS ONE*. 2021 Apr 29;16(4):e0250523.
- 637 51. Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY. Serial  
638 interval and incubation period of COVID-19: a systematic review and meta-analysis. *BMC*  
639 *Infect Dis*. 2021 Dec;21(1):257.
- 640 52. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al.  
641 Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. May  
642 RM, McLean AR, Pattison J, Weiss RA, editors. *Philos Trans R Soc Lond B Biol Sci*. 2004  
643 Jul 29;359(1447):1091–105.
- 644 53. Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L, et al. Clinical progression and  
645 viral load in a community outbreak of coronavirus-associated SARS pneumonia: a  
646 prospective study. *The Lancet*. 2003 May;361(9371):1767–72.
- 647 54. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et  
648 al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-  
649 2 infections: A living systematic review and meta-analysis. Ford N, editor. *PLOS Med*. 2020  
650 Sep 22;17(9):e1003346.

- 651 55. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al.  
652 Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome  
653 in Hong Kong. *The Lancet*. 2003 May;361(9371):1761–6.
- 654 56. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The  
655 evolution of SARS-CoV-2. *Nat Rev Microbiol*. 2023 Jun;21(6):361–79.
- 656 57. Hamilton DG, Hong K, Fraser H, Rowhani-Farid A, Fidler F, Page MJ. Prevalence  
657 and predictors of data and code sharing in the medical and health sciences: systematic review  
658 with meta-analysis of individual participant data. *BMJ*. 2023 Jul 11;e075767.
- 659 58. UKRI. UKRI open access policy [Internet]. 2023. Available from:  
660 <https://www.ukri.org/publications/ukri-open-access-policy/>
- 661 59. Imai N, Dorigatti I, Cori A, Donnelly C, Riley S, Ferguson N. Report 2: Estimating  
662 the potential total number of novel Coronavirus cases in Wuhan City, China [Internet].  
663 Imperial College London; 2020 Jan [cited 2024 Jul 23]. Available from:  
664 <http://spiral.imperial.ac.uk/handle/10044/1/77150>
- 665 60. Volz E, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunuba Perez Z, et al. Report  
666 5: Phylogenetic analysis of SARS-CoV-2 [Internet]. Imperial College London; 2020 Feb  
667 [cited 2024 Jul 23]. Available from: <http://spiral.imperial.ac.uk/handle/10044/1/77169>
- 668 61. Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of  
669 2019-novel coronavirus (nCoV) [Internet]. Imperial College London; 2020 Feb [cited 2024  
670 Jul 23]. Available from: <http://spiral.imperial.ac.uk/handle/10044/1/77154>
- 671
- 672
- 673
- 674





Figure 1: Study selection according to PRISMA guidelines and criteria described in SM-Table B.1. (Reasons for abstract exclusion not provided by Covidence).

675  
676  
677



678

679

680

681

682

683

684

685

686

687

Figure 2: Overview of the 2003-2004 SARS epidemic, based on final report of the Hong Kong SARS Expert Committee (10). Coloured countries and special administrative regions are those which reported confirmed SARS cases. Inset tables are shown for all locations with reported local SARS-CoV-1 transmission, indicating total cases, median age (except for China, for which median age was not reported), CFR, percentage of imported cases and dates of symptom onset of first and last case. In the bottom left corner, we report the mixed-effect logistic regression estimates of adjusted CFRs for locations with local transmission: red squares indicate location-specific estimates. Red diamonds represent overall common effect estimates - in which all aggregated data are assumed to come from a single data-generating process with one common CFR, and overall random effect estimates - that allow the CFR to vary by location and accordingly give different weights to each location in the overall estimate (SM-A.3.2). The “Events” column indicates the reported number of deaths. GLMM=generalised linear mixed-effects model (SM-A.3.2).





Figure 3: Overview of estimated SARS-CoV-1 (A) basic reproduction numbers ( $R_0$ ) and (B) effective reproduction numbers ( $R_t$ ). Circles represent mean estimates, and triangles represent unspecified central estimates. Thin black solid lines represent uncertainty estimates, and solid shaded bars represent ranges of central estimates reported, e.g. when disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods. Colours represent when during the outbreak the study was conducted, as extracted by reviewers. The vertical dashed line indicates the threshold value of 1. Estimates are labelled with the country of study. CHN = China, HKG = Hong Kong, SGP = Singapore, CAN = Canada, TWN = Taiwan, VNM = Vietnam. Outlying estimates from Kwok (2007) (33) and Moser (2015) (34) are not displayed. Only parameters from studies with a QA score > 0.5 are plotted.

688  
689  
690  
691  
692  
693  
694  
695

696

697




698

699

700 *Figure 4: Overview of estimated SARS (A) attack rates, (B) secondary attack rates, (C) growth rates, (D) overdispersion, (E) evolutionary rates, (F) substitution rates. Circles represent mean*  
701 *estimates, and triangles represent unspecified central estimates. Thin solid lines represent uncertainty estimates, and solid shaded bars represent ranges of central estimates reported, e.g. when*  
702 *disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods (e.g. compartmental, branching process models, etc). Colour represents (A & B) the*  
703 *study population considered, (C & D) when during the outbreak the study was conducted, with “control measures” referring to a time in the outbreak when interventions were reported to be in*  
704 *place, (E & F) long (L)/short (S) gene segment. In E and F, s/s/y refers to nucleotide substitutions per site per year. Only parameters from studies with a QA score > 0.5 are plotted.*





705  
706  
707  
708  
709  
710

Figure 5: Overview of SARS epidemiological delays: estimates of (A) mean serial interval, (B) mean infectious period, (C) mean duration from hospital admission to final health outcome (i.e. death or recovery); and meta-analysis of epidemiological delays: estimates of (D) mean incubation period, (E) mean duration from symptom onset to hospital admission. In panels A, B, & C, circles represent mean estimates, squares represent median estimates, and triangles represent unspecified central estimates. Thin solid lines represent uncertainty estimates, and solid shaded bars represent the range of central estimates reported, e.g. when disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods. In plot C, colour represents different final health outcomes. In D, blue squares indicate common effect and random effect estimates across different study populations, and blue diamonds represent: overall

*common effect estimates - in which all aggregated data are assumed to come from a single data-generating process, and overall random effect estimates. In E, blue squares represent study-specific estimates, and blue diamonds represent overall common effect and random effect estimates. Only parameters from studies with a QA score > 0.5 are plotted.*

711  
712  
713